Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2243794 | 1.00 | LMNA (0.48) | LMNAHKDC1AOC3TRPA1POLB | |
| SCHEMBL11427004 | 0.84 | LMNA (0.45) | LMNAHKDC1AOC3TRPA1KDM4E | |
| SCHEMBL28545770 | 0.84 | LMNA (0.45) | LMNAHKDC1AOC3TRPA1KDM4E | |
| SCHEMBL4109477 | 0.82 | STAT3 (0.35) | LMNAPOLBMEN1KMT2AATM | |
| SCHEMBL4104012 | 0.81 | CYP1A2 (0.55) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL11981273 | 0.81 | CYP1A2 (0.55) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4104011 | 0.81 | CYP1A2 (0.55) | LMNAMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL691654 | 0.81 | TRPA1 (0.47) | LMNAAOC3TRPA1KDM4EADRA2A | |
| SCHEMBL691655 | 0.81 | TRPA1 (0.47) | LMNAAOC3TRPA1KDM4EADRA2A | |
| SCHEMBL11001287 | 0.81 | LMNA (0.40) | LMNAAOC3TRPA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201732-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Allyl Alcohols-Acroleins and use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-08-18 | — | — | US | claimed |
| US-20110201733-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Allyl Alcohols and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-08-18 | — | — | US | claimed |
| US-8569524-B2 | Bis(tetrahydrofuran) compound, method for production of the compund, and use of the compound | GLYTECH INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2123655-B1 | BIS(TETRAHYDROFURAN) COMPOUND, METHOD FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | OTSUKA CHEMICAL CO LTD (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20100105931-A1 | BIS(TETRAHYDROFURAN) COMPOUND, METHOD FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | OTSUKA CHEMICAL CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2123655-A1 | BIS(TETRAHYDROFURAN) COMPOUND, METHOD FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | Otsuka Chemical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| US-4791183-A | 1,2-DIHALOETHYL STYRENES | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | LMNA 3740/4885HKDC1 4519/4885AOC3 3400/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | LMNA 4860/4885HKDC1 2583/4885AOC3 3669/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | LMNA 4860/4885HKDC1 2583/4885AOC3 3669/4885 |
| US-20100105931-A1 | BIS(TETRAHYDROFURAN) COMPOUND, METHOD FOR PRODUCTION OF THE COMPOUND, AND USE OF THE COMPOUND | BDNF, NGF, NTRK2 | LMNA 3486/4885HKDC1 2379/4885AOC3 197/4885 |
| US-20110201733-A1 | Method for Producing Mono-Hydroxyfunctionalized Dialkylphosphinic Acids and Esters and Salts Thereof By Means of Allyl Alcohols and Use Thereof | HAO2, ALOX5, AOC3 | LMNA 4153/4885HKDC1 3791/4885AOC3 3/4885 |
| US-20110201732-A1 | Method for Producing Dialkylphosphinic Acids and Esters and Salts Thereof by Means of Allyl Alcohols-Acroleins and use Thereof | AOC3, SCO2, AOC2 | LMNA 3543/4885HKDC1 3614/4885AOC3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.